Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

John F. Seymour, MD, Rena Buckstein, MD, Valeria Santini, MD, Hartmut Döhner, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Ching-Yuan Kuo, MD, Dina Ben-Yehuda, MD, Joan Bargay, MD, Stephen Songer, PharmD, Jerry Weaver, PhD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 2818.

https://doi.org/10.1182/blood.V128.22.2818.2818

Published: 2016

Journal Articles

High Titers of Hepatitis B Surface Antibodies Indicating Low Risk of Hepatitis B Virus-Related Hepatitis in Lymphoma Patients Treated with Rituximab-Based Chemotherapy

Sung-Nan Pei, MD, Ming-Chung Wang, MD, Ming-Chung Ma, MD, Ching-Yuan Kuo, MD, Chien-Hung Chen, Po-Nan Wang, MD

Blood (2015) 126 (23): 3869.

https://doi.org/10.1182/blood.V126.23.3869.3869

Published: 2015

Journal Articles

Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan

Ching-Yuan Kuo, MD, Po-Nan Wang, MD, Wen Li Hwang, MD, Cheng-Hwai Tzeng, MD, Li-Yuan Bai, MD, Jih-Luh Tang, MD PhD, Ming-Chih Chang, MD, Sheng-Fung Lin, MD, Tsai-Yun Chen, MD, Yeu-Chin Chen, MD, Tran-Der Tan, MD, Chih-Yi Hseih, MD, Chinjune Lin, MD, Miljkovic Darko, MD, Chang Cheng-Shyong, MD

Blood (2015) 126 (23): 1593.

https://doi.org/10.1182/blood.V126.23.1593.1593

Published: 2015

Journal Articles

Pegylated Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory and/or Elder Acute Myeloid Leukemia: The Preliminary Result of Phase II Trial

Hui-Jen Tsai, MD PhD, Ming-Chung Wang, MD, Sheng-Fung Lin, MD, Ya-Ping Chen, MD PhD, Hui-Hwa Hsiao, MD PhD, Ching-Yuan Kuo, MD, Li-Tzong Chen, MD PhD, Tsai-Yun Chen, MD

Blood (2014) 124 (21): 984.

https://doi.org/10.1182/blood.V124.21.984.984

Published: 2014

Journal Articles

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Ming-Chung Kuo, MD, Tsai-Yun Chen, MD, Ming-Chung Wang, MD, Youngsen Yang, MD, Su-Peng Yeh, MD, Cheng-Shyong Chang, MD, Yii-Jenq Lan, MD, Chih-Cheng Chen, MD, Yu-Chieh Su, MD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, MD, Li-Yuan Bai, MD, Wen-Li Hwang, MD, Lee-Yung Shih, MD

Blood (2014) 124 (21): 4544.

https://doi.org/10.1182/blood.V124.21.4544.4544

Published: 2014

NARROW

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

High Titers of Hepatitis B Surface Antibodies Indicating Low Risk of Hepatitis B Virus-Related Hepatitis in Lymphoma Patients Treated with Rituximab-Based Chemotherapy

Pegylated Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory and/or Elder Acute Myeloid Leukemia: The Preliminary Result of Phase II Trial

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

High Titers of Hepatitis B Surface Antibodies Indicating Low Risk of Hepatitis B Virus-Related Hepatitis in Lymphoma Patients Treated with Rituximab-Based Chemotherapy

Pegylated Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory and/or Elder Acute Myeloid Leukemia: The Preliminary Result of Phase II Trial

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only